 |
市場調査レポート
商品コード
1454151
がん腫瘍プロファイリングの世界市場規模、シェア、成長分析、技術別、がんタイプ別-産業予測、2024～2031年Global Cancer Tumor Profiling Market Size, Share, Growth Analysis, By Technology(Breast cancer, Lung cancer), By Cancer type(genomic biomarker, protein biomarker) - Industry Forecast 2024-2031 |
||||||
| がん腫瘍プロファイリングの世界市場規模、シェア、成長分析、技術別、がんタイプ別-産業予測、2024～2031年 |
|
出版日: 2024年03月11日
発行: SkyQuest
ページ情報: 英文 219 Pages
納期: 3～5営業日
|
- 全表示
- 概要
- 目次
がん腫瘍プロファイリングの世界市場規模は2022年に107億3,000万米ドルと評価され、予測期間（2024～2031年）のCAGRは10.6%で、2023年の118億7,000万米ドルから2031年には265億7,000万米ドルに成長する展望です。
がん腫瘍プロファイリング市場を促進する主要要因は、世界のがん患者の増加と腫瘍プロファイリングにおけるバイオマーカーの応用です。がん腫瘍プロファイリング市場は、がん研究への投資の増加、資金提供プログラム、技術開発の結果として拡大しています。市場参入企業にとって、ポイントオブケア診断と個別化医療の拡大は、今後数年間で大きな可能性をもたらすと予想されます。
2020年から2021年にかけてのCOVID-19パンデミックは、がん腫瘍プロファイリング業界に大きな影響を及ぼすとは予想されていないです。ウイルスに対する予防措置がとられた結果、COVID-19の流行はがんの試験と診断を大幅に減少させました。プロテオミクス、エピジェネティクス、メタボロミクス、ゲノミクスは、がん腫瘍プロファイリング市場の予測期間に含まれるセグメントです。このうち、ゲノミクスは複合年間成長率（19.7％）が最大になると予想されています。この方法は、全ゲノム内の遺伝子が異常か正常かを確定します。遺伝子の特徴を明らかにするために用いられます。遺伝子は突然変異によって異常発生し、がん細胞の生存を助けることがあります。がんを特定し調査するための有望な方法は、腫瘍の形態、代謝、病期の変化を調べるがん腫瘍プロファイリングと言われています。
目次
エグゼクティブサマリー
- 市場概要
- 繁栄と衰退
調査手法
- 情報調達
- セカンダリとプライマリデータソース
- 市場規模の推定
- 市場の前提条件と制限
親市場の分析
- 市場概要
- 市場規模
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
主要市場の考察
- 技術分析
- 価格分析
- サプライチェーン分析
- バリューチェーン分析
- 市場のエコシステム
- IP分析
- 貿易分析
- スタートアップ分析
- 原材料の分析
- イノベーションマトリクス
- パイプライン製品の分析
- マクロ経済指標
- 主要投資の分析
- 主要成功要因
- 競合の程度
市場力学と展望
- 市場力学
- 促進要因
- 機会
- 抑制要因
- 課題
- 規制情勢
- ポーターの分析
- 将来の混乱についての特別な考察
がん腫瘍プロファイリングの世界市場：技術別
- 市場概要
- 乳がん
- 肺がん
- 結腸直腸がん
がん腫瘍プロファイリングの世界市場：がんタイプ別
- 市場概要
- ゲノムバイオマーカー
- タンパク質バイオマーカー
がん腫瘍プロファイリングの世界市場規模：地域別
- 市場概要
- 北米
- 米国
- カナダ
- 欧州
- ドイツ
- スペイン
- フランス
- 英国
- その他の欧州地域
- アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他のアジア太平洋
- ラテンアメリカ
- ブラジル
- その他のラテンアメリカ地域
- 中東・アフリカ
- GCC諸国
- 南アフリカ
- その他中東・アフリカ地域
競合情勢
- 上位5社の比較
- 主要企業の市場ポジショニング（2021年）
- 主要市場企業が採用した戦略
- 主要成功戦略
- 市場における最近の活動
- 主要企業の市場シェア（2021年）
主要企業プロファイル
- Illumina, Inc.
- Thermo Fisher Scientific, Inc.
- QIAGEN N.V.
- F. Hoffmann-La Roche AG
- Agilent Technologies, Inc.
- Myriad Genetics, Inc.
- Personal Genome Diagnostics Inc.
- Foundation Medicine, Inc.
- Guardant Health, Inc.
- NanoString Technologies, Inc.
- Genomic Health, Inc.
- Adaptive Biotechnologies Corporation
- Caris Life Sciences
- Becton, Dickinson and Company
- PerkinElmer, Inc.
- Natera, Inc.
- Oxford Nanopore Technologies
- Biocartis Group NV
- ArcherDX, Inc.
- Sysmex Corporation
Global Cancer Tumor Profiling Market size was valued at USD 10.73 billion in 2022 and is poised to grow from USD 11.87 billion in 2023 to USD 26.57 billion by 2031, at a CAGR of 10.6% during the forecast period (2024-2031).
The main drivers propelling the market for cancer detection and treatment products are the global increase in cancer cases and the application of biomarkers in tumor profiling. The market for cancer and tumor profiling has expanded as a result of increased investments in cancer research, funding programs, and technology developments. For market participants, the expansion of point-of-care diagnostics and personalized medicine is anticipated to present substantial potential over the next years.
The COVID-19 pandemic in 2020-2021 is not anticipated to have a major effect on the cancer/tumor profiling industry. As a result of precautions made to guard against the virus, the COVID-19 epidemic has significantly reduced the amount of cancer testing and diagnoses. Proteomics, epigenetics, metabolomics, and genomics are the segments of the cancer/tumor profiling market that will be included in the forecast period. Of these, genomics is anticipated to have the greatest compound annual growth rate (19.7%). The method establishes if a gene within the entire genome is aberrant or normal. It is used to characterize genes. Genes develop abnormally due to mutations, which can aid in the survival of cancer cells. A promising method for identifying and researching cancer is cancer tumor profiling, which looks for alterations in tumor shape, metabolism, and stage.
Top-down and bottom-up approaches were used to estimate and validate the size of Global Cancer Tumor Profiling Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Logistics Automation Market Segmental Analysis
The market for cancer tumor profiling is divided into segments based on according to application, biomarker, cancer kind, and technology. On the other hand, technology is divided into categories such as microarrays, mass spectrometry, in-situ hybridization, polymerase chain reaction, next-generation sequencing, and immunoassays.Breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma cancer, and other cancer types are divided into different categories. Protein biomarkers and genetic biomarkers are the two categories of biomarkers. Application is divided into two categories: research and biomarker identification. The market is divided into five regions: North America, Europe, Asia Pacific, Latin America, and Middle East and Africa.
Drivers of Global Cancer Tumor Profiling Market
One of the main factors driving market expansion in the overall cancer/tumor profiling industry is the rise in cancer incidences. Numerous causes contribute to the rising incidence of cancer. The disease is broad and complex, with multiple etiologies. The incidence of cancer is influenced by factors such as aging populations, increasing population sizes, and shifting rates of certain cancer causes.
Restraints in Global Cancer Tumor Profiling Market
In the cancer and tumor profiling industry, technical problems with sample collection and storage are impeding market expansion. A rapidly expanding area of medicine called "personalized medicine" is revolutionizing the diagnosis, categorization, and management of numerous illnesses. The way diseases are treated is already significantly changing as a result of the widespread adoption of this strategy in clinical practice. Oncology is one field where recent advancements in cancer treatment are very noticeable. Their associated risks may impede market expansion.
Market Trends of Global Cancer Tumor Profiling Market
The integration of omics data and developments in liquid biopsy tests are anticipated to drive the greatest compound annual growth rate (CAGR) in the cancer/tumor profiling market over the projected period. The topic of personalized medicine is a rapidly expanding area of healthcare study that is revolutionizing the diagnosis, classification, and treatment of diseases. It is currently utilized to treat a wide range of illnesses and has entered the mainstream of clinical practice. Oncology is one field where the advancements in cancer treatment are most noticeable.
Table of Contents
Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
- Regulatory Landscape
- Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
- Political Impact
- Economic Impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Global Cancer Tumor Profiling Market by Technology
- Market Overview
- Breast cancer
- Lung cancer
- Colorectal cancer
Global Cancer Tumor Profiling Market by Cancer type
- Market Overview
- genomic biomarker
- protein biomarker
Global Cancer Tumor Profiling Market Size by Region
- Market Overview
- North America
- USA
- Canada
- Europe
- Germany
- Spain
- France
- UK
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
- By Development
- By Company
- By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- Illumina, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Thermo Fisher Scientific, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- QIAGEN N.V.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- F. Hoffmann-La Roche AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Agilent Technologies, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Myriad Genetics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Personal Genome Diagnostics Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Foundation Medicine, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Guardant Health, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- NanoString Technologies, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Genomic Health, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Adaptive Biotechnologies Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Caris Life Sciences
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Becton, Dickinson and Company
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- PerkinElmer, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Natera, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Oxford Nanopore Technologies
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biocartis Group NV
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- ArcherDX, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sysmex Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
